<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">OLANZAPINE</span><br/>(o-lan'za-peen)<br/><span class="topboxtradename">Zyprexa, </span><span class="topboxtradename">Zyprexa Zydis, </span><span class="topboxtradename">Zyprexa IntraMuscular<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">psychotherapeutic agent</span>; <span class="classification">antipsychotic agent</span>; <span class="classification">atypical</span>; <span class="classification">selective serotonin reuptake inhibitor</span>; <span class="classification">dopamine-reuptake inhibitor</span><br/><b>Prototype: </b>Clozapine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg tablets; 10 mg, 15 mg, 20 mg orally-disintegrating tablets; 10 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Antipsychotic activity is thought to be due to antagonism for both serotonin 5HT<sub>2A/2C</sub> and dopamine D<sub>14</sub> receptors. May inhibit the CNS presynaptic neuronal reuptake of serotonin and dopamine. Antagonism of alfa-adrenergic receptors
         results in the adverse effect of orthostatic hypotension.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces antipsychotic and anticholinergic activity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of psychotic disorders, treatment of bipolar disorder, acute agitation (IM).</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Alzheimer's dementia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to olanzapine; abrupt discontinuation, coma, severe CNS depression, subcutaneous or intramuscular injection
         of olanzapine; tardive dyskinesia; infants, pregnancy (category C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Known cardiovascular disease, neurological disease, stroke, cerebrovascular disease, Parkinson disease, dementia; history
         of seizures, conditions that predispose to hypotension (i.e., dehydration, hypovolemia); history of syncope; history of breast
         cancer; Japanese; diabetes mellitus; prostatic hypertrophy; closed-angle glaucoma; paralytic ileus; urinary retention; hepatic
         or renal impairment, concurrent use of hepatotoxic drugs, jaundice; predisposition to aspiration pneumonia; may increase risk
         of stroke in elderly patients with dementia; history of or high risk for suicide. Safety and effectiveness in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Psychotic Disorders</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 510 mg once/d, may increase by 2.55 mg q wk until desired response (usual range 1015 mg/d, max:
               20 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 5 mg once/d<br/><br/><span class="indicationtitle">Bipolar Mania</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 1015 mg once/d, may increase by 5 mg q24h if needed<br/><br/><span class="indicationtitle">Acute Agitation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IM</span> 10 mg, do not repeat more frequently than q2h (max: 30 mg/24h)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">IM</span> 2.55 mg once<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not push orally disintegrating tablet through blister foil. Peel foil back and remove tablet. Tablet will disintegrate
            with/without liquid.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Weight gain,</span> fever, back and chest pain, peripheral and lower extremity edema, joint pain, twitching, premenstrual syndrome. <span class="typehead">CNS:</span> <span class="speceff-common">Somnolence, dizziness, headache, agitation, insomnia, nervousness, hostility,</span> anxiety, personality disorder, akathisia, hypertonia, tremor amnesia, euphoria, stuttering, extrapyramidal symptoms (dystonic
      events, <span class="speceff-common">parkinsonism, akathisia</span>), tardive dyskinesia. <span class="typehead">CV:</span> Postural hypotension, hypotension, tachycardia. <span class="typehead">Special Senses:</span> Amblyopia, blepharitis. <span class="typehead">GI:</span> Abdominal pain, constipation, dry mouth, increased appetite, increased salivation, nausea, vomiting, elevated liver function
      tests. <span class="typehead">Metabolic:</span> Hyperglycemia, diabetes mellitus. <span class="typehead">Urogenital:</span> Premenstrual syndrome, hematuria, urinary incontinence, metrorrhagia. <span class="typehead">Respiratory:</span> Rhinitis, cough, pharyngitis, dyspnea. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May enhance hypotensive effects of <span class="classification">antihypertensives</span>. May enhance effects of other CNS <span class="classification">active drugs</span>, <b>alcohol.</b> <b>Carbamazepine,</b> <b>omeprazole,</b> <b>rifampin</b> may increase metabolism and clearance of olanzapine. <b>Fluvoxamine</b> may inhibit metabolism and clearance of olanzapine. <span class="typehead">Herbal:</span> <b>St. John's wort</b> may cause <b>serotonin</b> syndrome (headache, dizziness, sweating, agitation). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract, 60% reaches systemic circulation. <span class="typehead">Onset:</span> 15 min IM. <span class="typehead">Peak:</span> 6 h. <span class="typehead">Distribution:</span> 93% protein bound, secreted into breast milk of animals (human secretion unknown). <span class="typehead">Metabolism:</span> Metabolized in liver, primarily by cytochrome P450 1A2 (CYP1A2). <span class="typehead">Elimination:</span> Approximately 57% excreted in urine, 30% in feces. <span class="typehead">Half-Life:</span> 2154 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor diabetics for loss of glycemic control.</li>
<li>Withhold drug and immediately report S&amp;S of neuroleptic malignant syndrome (see Appendix F); assess for and report S&amp;S of
            tardive dyskinesia (see Appendix F).
         </li>
<li>Lab tests: Periodically monitor ALT, especially in those with hepatic dysfunction or being treated with other potentially
            hepatotoxic drugs. Periodic blood glucose monitoring.
         </li>
<li>Monitor BP and HR periodically. Monitor temperature, especially under conditions such as strenuous exercise, extreme heat,
            or treatment with other anticholinergic drugs.
         </li>
<li>Monitor for seizures, especially in older adults and cognitively impaired persons.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Carefully monitor blood glucose levels if diabetic.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known; drug increases risk of orthostatic
            hypotension and cognitive impairment.
         </li>
<li>Learn common adverse effects and possible drug interactions.</li>
<li>Avoid alcohol and do not take additional medications without informing physician.</li>
<li>Do not become overheated; avoid conditions leading to dehydration.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>